Laurent Fischer - 11 Aug 2026 Form 4 Insider Report for Lycia Therapeutics, Inc.

Reporting relationship: Director
Issuer ticker: N/A
Reported as of: 11 Aug 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 26 Oct 2026, 19:07:26 UTC
Prior SEC filing: 17 Jun 2026
Next SEC filing: 11 Sep 2026
Source filing: View source filing
Reporting owner signature: /s/ Amy Bachrodt, Attorney-in-Fact

Filing notes and source

Key filing fact

Laurent Fischer filed Form 4 for Lycia Therapeutics, Inc. on 26 Oct 2026.

Key facts

This page summarizes Laurent Fischer's Form 4 filing for Lycia Therapeutics, Inc..
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 26 Oct 2026, 19:07.

Change

Previous filing in this sequence was filed on 17 Jun 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001379344 Primary reporting owner

Fischer Laurent

Relationship: Director
Address: C/O LYCIA THERAPEUTICS, INC., 400 EAST JAMIE COURT, SUITE 200, SOUTH SAN FRANCISCO
Signature: /s/ Amy Bachrodt, Attorney-in-Fact
Signature date: 26 Oct 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

No ticker transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +13,307
Change %
Price: $0.000000^*
Shares after: 13,307
Date: 11 Aug 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 13,307
Exercise price: $3.70
Footnotes: F1, F2

No ticker transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +20,000
Change %
Price: $0.000000^*
Shares after: 20,000
Date: 22 Oct 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 20,000
Exercise price: $18.00
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

The transaction occurred prior to the Issuer's registration of a class of equity securities under Section 12 of the Exchange Act in connection with the Issuer's initial public offering, and the transaction is reported herein pursuant to Rule 16a-2(a).

Footnote F2

The options vest as to 1/48 of the total award monthly over four years, with the first tranche vested on September 6, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Footnote F3

The options will vest as to 100% of the award on October 22, 2027, subject to the Reporting Person's provision of service to the Issuer on such vesting date.